PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
06-Mar-2020 Hospital PUC-Campinas Celso Pierro joins Patient Network Explorer, expanding Clinerion’s existing patient coverage in Brazil. Clinerion Ltd.
06-Mar-2020 Birmingham researcher awarded £1.68m to fund research in ‘raised brain pressure’ University of Birmingham
06-Mar-2020 GLOBAL GROWTH OF AROUND $900 MILLION A YEAR FOR DATA VISUALISATION MARKET Zegami
06-Mar-2020 As coronavirus spreads, mitigation may be better strategy than quarantine, says GlobalData GlobalData
06-Mar-2020 New hVIVO contract signed with a European Biotech Company Open Orphan plc
04-Mar-2020 Notice of Preliminary Results Ergomed plc
04-Mar-2020 Interim Results for the six months ended 31 December 2019 Allergy Therapeutics plc
04-Mar-2020 Abcam extends assay and labelling capabilities with the acquisition of Marker Gene Technologies Abcam
04-Mar-2020 New disinfection spray from Lipidor and Aurena Laboratories Lipidor AB
04-Mar-2020 HRA Pharma expands into South Africa with Compeed(R) HRA Pharma
04-Mar-2020 TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis TISSIUM
04-Mar-2020 Account Executive Discovery PR
04-Mar-2020 Cytel champions precision oncology master protocol trial designs Cytel
03-Mar-2020 Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs Chi-Med
03-Mar-2020 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress Autolus Therapeutics plc
03-Mar-2020 Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Takeda Pharmaceutical Company Limited
03-Mar-2020 PolyProx Therapeutics raises an additional £1 million seed financing from new investor, LifeArc, to validate polyproxin® drug leads in oncology PolyProx Therapeutics
03-Mar-2020 GE Healthcare Life Sciences to manufacture RevoluGen’s Fire Monkey / Fire Flower product for enabling long-read DNA sequencing GE Healthcare Life Sciences
03-Mar-2020 Gilead Sciences entered into a definitive agreement to acquire Forty Seven for $95.50 per share in cash, or approximately $4.9 billion, further boosting the company's immuno-oncology presence. Gilead Sciences
03-Mar-2020 Celltrion Healthcare launch Remsima® SC in UK Celltrion Healthcare